Comienzos
keyboard_arrow_right
keyboard_arrow_right
A head in the field of regenerative medicine.
Specialist

A head in the field of regenerative medicine.

Action receives UK MHRA clearance for hESC-derived RPE cell trial for Stargardt’s Macular Dystrophy Advanced Cell Technology, Inc. ;, a head in the field of regenerative medicine, announced today that it has received clearance from the U.K. Medicines and Healthcare items Regulatory Company to begin with treating patients within a Phase 1/2 clinical trial for Stargardt’s Macular Dystrophy using retinal pigment epithelium derived from individual embryonic stem cells . ACT received similar approval from the Gene Therapy Advisory Committee , which includes responsibility for the ethical oversight of proposals to carry out scientific trials including gene or stem cell therapies in the U.K.Related StoriesFirst hospital installs Ortho Vision AnalyzerNew UCLA study looks at primary care medical home in reducing childrens' repeat appointments to hospitalsBoston Children's and Rock Health synergy to accelerate advancement of pediatric health systems’Even though we were pleased by the overall performance of our Gamma Knife and IGRT business in Turkey since we entered the marketplace in 2011, we’ve decided to focus our administration and financial resources on the advancement of our far larger domestic Gamma Knife business and our exciting growth chance in proton therapy. We are glad that Euromedic will continue providing Gamma IGRT and Knife services in Turkey, which we believe is usually a market with substantial potential.